Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900929 | 0.86 | P2RX7 (0.48) | P2RX7RAB9AHPGDGPR139NPC1 | |
| SCHEMBL279847 | 0.84 | NPC1 (0.51) | P2RX7RAB9AHPGDNPC1CA1 | |
| SCHEMBL12163930 | 0.83 | LMNA (0.53) | P2RX7RAB9AHPGDNPC1KDM4E | |
| SCHEMBL15630975 | 0.83 | EGLN1 (0.57) | EGLN1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL8002583 | 0.83 | ALDH1A1 (0.64) | EGLN1P2RX7HPGDGPR139CA1 | |
| SCHEMBL20355604 | 0.82 | EGLN1 (0.64) | EGLN1RAB9AKDM4EMEN1LMNA | |
| SCHEMBL29195047 | 0.82 | P2RX7 (0.55) | EGLN1P2RX7RAB9AHPGDGPR139 | |
| SCHEMBL18850119 | 0.82 | GPR139 (0.47) | P2RX7RAB9AHPGDGPR139KDM4E | |
| SCHEMBL12901002 | 0.82 | NPC1 (0.55) | P2RX7RAB9AHPGDNPC1CA1 | |
| SCHEMBL20694515 | 0.81 | HPGD (0.62) | EGLN1P2RX7HPGDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879887-B2 | such as 2-(4-chloro-3-hydroxyphenylamino)-N-(6H-pyrazolo[4',3':3,4]benzo[1,2-d]thiazol-2-yl)-acetamide, having antitumor activity, particularly dual inhibitory activity on Aurora kinase and cyclin-dependent kinase (CDK), and are useful for cell proliferative diseases such as cancer | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2045253-A1 | a-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | Nissan Chemical Industries, Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CCNA1, AURKA, CDK1 | EGLN1 3438/4885P2RX7 2996/4885RAB9A 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.